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Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, but the overall prognosis
remains disappointing especially in the advanced-stage patients. Aberration expression of Aurora kinases
is tumorigenic and thus it has attracted interests as therapeutic targets in cancer treatment. Here, we
investigated the proteomic response of HCC Hep3B cells to danusertib (Danu), a pan-Aurora kinase
inhibitor, and then validated the proteomic results based on stable-isotope labeling by amino acids in cell
culture (SILAC). The proteomic data identified that Danu modulated the expression of 542 protein
molecules (279 up-regulated; 260 down-regulated; 3 stable). Ingenuity pathway analysis (IPA) and KEGG
pathway analysis identified 107 and 24 signaling pathways were regulated by Danu, respectively. IPA
analysis showed cellular growth and proliferation, and cell death and survival were among the top five
molecular and cellular functions regulated by Danu. The verification experiments showed that Danu
inhibited the proliferation of Hep3B cells with a 24-hr IC50 value of 22.03 µM. Danu treatment also
arrested Hep3B cells in G2/M phase via regulating the expression of key cell cycle regulators and induced
apoptosis via mitochondria-dependent pathway in a dose-dependent manner. Besides, Danu induced a
marked autophagy, and inhibition of autophagy enhanced the anticancer effects of Danu, indicating a
cyto-protective role of Danu-induced autophagy. Our proteomic data and Western blotting assays
showed the PI3K/Akt/mTOR signaling pathway was involved in the inducing effect of Danu on apoptosis
and autophagy. Collectively, our findings have demonstrated that the Aurora kinases inhibition with
danusertib results in global proteomic response and exerts anticancer effects in Hep3B cells involving
regulation of cell cycle, apoptosis and autophagy and associated signaling pathways.
Key words: Hepatocellular carcinoma; Aurora kinases; danusertib; cell cycle; apoptosis; autophagy, quantitative
proteomics.

Introduction
Liver cancer is a major malignancy burden and
global public health problem [1, 2]. According to the
GLOBOCAN 2012 by World Health Organization,

there were 782,500 new cases of liver cancer
(accounting for 5.6% of all cancers) and 745,500 liver
cancer-caused deaths (9.1% of total) globally in 2012
http://www.jcancer.org
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[3]. This malignancy is the 5th most common cancer in
men (554,000 cases) and the 9th in women (228,000
cases). According to the National Cancer Institute,
40,710 patients would be diagnosed with liver cancer
in the United States (US) in 2017 and 28,920 would die
of this disease. Liver cancer is the 10th most common
cancer and the 5th most common cause of cancer
death among men; incidence of liver cancer has
tripled in the US since 1980 [4]. In China, liver cancer
is the 4th most common cancer after lung, stomach,
and esophagus cancer; it is the 3rd leading cause of
cancer-related death after lung and stomach cancer
[5]. The estimated new liver cancer cases were 466,100
(343,700 men and 122,300 women) and estimated
deaths due to liver cancer were 422,100 (310,600 men
and 111,500 women) in China in 2015 [5]. The overall
5-year survival rate for liver cancer patients is ∼18%;
for liver cancer patients who are diagnosed at an early
stage, the 5-year survival rate is 31%; but the 5-year
survival rate drops down to only 3% if the cancer has
metastasized in liver cancer patients in the US [6]. The
main risks of liver cancer in the US are liver cirrhosis
and nonalcoholic fatty liver disease; whereas hepatitis
B and C infection and aflatoxin exposure are the major
risk factors for liver cancer in China [7, 8].
Hepatocellular carcinoma (HCC) accounts for 85-90%
of all liver cancers, which can be divided into two
subclasses: proliferative and non-proliferative, each
depending on distinct pathways [9, 10]. Mutations in
the TERT promoter, p53, ARID1A, CDKN2A,
CTNNB1, AXIN1, and CCND1 are very common in
HCC [7, 8, 10]. Critical molecular events in HCC
pathogenesis include activated WNT signaling
pathway due to mutations in CTNNB1 and AXIN1,
alterations in p53 and the PI3K/Akt/mTOR
pathways, aberrant cell cycle regulation and
angiogenesis, and epigenetic changes [10]. The main
treatment modalities for HCC include surgery,
radiofrequency ablation, percutaneous ethanol
injection, radiation therapy, chemoembolization and
radioembolization,
targeted
therapy,
and
immunotherapy [7, 11-15]. To date, only sorafenib
(Nexavar, co-developed by Bayer and Onyx
Pharmaceuticals Inc.) and regorafenib (Stivarga,
developed by Bayer HealthCare Pharmaceuticals
Inc.), two targeted multi-kinase inhibitors, have been
approved by the Food and Drug Administration
(FDA) to treat HCC patients [16]. Sorafenib has been
used as a first-line therapy in patients with advanced
stage HCC for a decade and has set the stage for
personalized targeted therapy [15, 17]. Its role has
ranged from monotherapy to neoadjuvant and
adjuvant treatment with surgical resection, liver
transplantation and chemoembolization. Regorafenib
inhibits multiple kinases involved in tumor
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proliferation and angiogenesis, causing a survival
benefit as a second-line therapy in HCC when
sorafenib fails [16, 18]. However, tumor resistance and
adverse effects are two major limiting factors for the
targeted therapy of liver cancer [19]; the overall
prognosis remains dismal in patients with late-stage
liver cancer. Therefore, seeking new therapeutic
agents for advanced HCC is still mandatory.
Aurora kinases, consisting of three family
members, Aurora kinase A, B and C, are one of the
serine-threonine kinases and involved in multiple
mitotic events [20]. In recent years, aberrant
expression of these kinases has been proved to be
tumorigenic in many types of cancer, including HCC
[21, 22]. Targeting Aurora kinase has become an
attractive target for new anticancer treatments and
many Aurora kinase inhibitors have been developed
and evaluated in preclinical to clinical studies [23-26].
Recently, we have found that the Aurora kinase A
inhibitor alisertib induces autophagy and cell cycle
arrest and enhances chemosensitivity in HepG2 cells
[27]. Furthermore, we have reported that danusertib
(Danu) [28], a small molecule pan-Aurora kinase
inhibitor, kills ovarian, gastric and breast cancer and
leukemia cells via induction of apoptosis and
autophagy involving AURKB/p70S6K/RPL15 and
PI3K/Akt/mTOR signaling pathways [29-32]. Several
Phase I and II studies have shown that Danu has
limited efficacy but is well tolerated by cancer patients
[33-37]. However, the evidence on its effects on HCC,
especially the effect on the global proteomic response,
is still limited.
Mass
spectrometry-based
proteomics
is
increasingly employed in a quantitative way to
investigate protein expression changes in biological
samples, often based on labeling of samples with
stable isotopes that are introduced chemically or
metabolically. Stable-isotope labeling by amino acids
in cell culture (SILAC) is a powerful and increasingly
popular approach for quantitative proteomics studies
in vitro and in vivo [38-41]. In the SILAC study, two
cell populations are cultured in the presence of heavy
or light amino acids (typically lysine and/or
arginine), one of them is subject to a perturbation (e.g.
drug exposure), and then both are combined,
processed, and analyzed. Incorporation of the "heavy"
amino acid occurs through cell growth, protein
synthesis, and turnover. SILAC allows "light" and
"heavy" proteomes to be distinguished by mass
spectrometry
while
avoiding
any
chemical
derivatization and associated purification. SILAC can
be applied to systemically evaluate global protein
profile, investigate and identify the target networks of
drugs, drug toxicity, and new biomarkers for diseases
[40, 42, 43]. The purpose of this study was to evaluate
http://www.jcancer.org
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the proteomic responses and validated the molecular
targets of Danu in Hep3B cells using a combination of
proteomic and cell-based approaches, with a focus on
cell cycle progression, apoptosis, and autophagy.

Materials and methods
Chemicals and Reagents
Danu was purchased from Selleckchem Inc
(Houston, TX, USA). Dulbecco’s phosphate buffered
saline (PBS), fetal bovine serum (FBS), thiazolyl blue
tetrazolium bromide (MTT), RNase A, propidium
iodide, 13C6 L-lysine, 13C6 15N4 L-arginine and
L-arginine, and chloroquine (CQ) were purchased
from Sigma-Aldrich Inc. (St Louis, MO, USA).
Dulbecco’s Modified Eagle’s Medium (DMEM) was
obtained from Corning Cellgro Inc (Herndon, VA,
USA). Phenol red-free culture medium and
4,6-diamidino-2-phenylindole were bought from
Invitrogen Inc. (Carlsbad, CA, USA). The Cyto-ID®
autophagy detection kit was obtained from Enzo Life
Sciences Inc. (Farmingdale, NY, USA). The Pierce
bicinchoninic acid (BCA) protein assay kit, skim milk,
and Western blot substrate were purchased from
Thermo Scientific Inc. (Waltham, MA, USA).
Polyvinylidene difluoride (PVDF) membrane was
purchased from EMD Millipore Inc. (Bedford, MA,
USA). Primary antibodies against human cyclin B1,
p-cyclin B1 at Ser 133, cell division cycle protein 2
homologue (CDC2), p-CDC2 at Tyr15, p-CDC25C at
Ser216,
cytochrome
c,
Bcl-2-like
protein
4/Bcl-2-associated X protein (Bax), B-cell lymphomaextra large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), cleaved
caspase 9, cleaved caspase 3, p53 up-regulated
modulator of apoptosis (PUMA), cleaved poly-ADPribose polymerase (cleaved-PARP), Akt, p-Akt at
Ser473, mammalian target of rapamycin (mTOR),
p-mTOR at Ser2448, PI3K, p-PI3K/p85 at Tyr458,
beclin1,
SQSTM1/p62,
microtubule-associated
protein 1A/1B-light chain 3 (LC3)-I, and LC3-II were
all purchased from Cell Signaling Technology Inc.
(Beverly, MA, USA). The antibody against human
β-actin was obtained from Santa Cruz Biotechnology
Inc. (Santa Cruz, CA, USA).

Cell line, cell culture and Danu treatment
Hep3B cells were obtained from the American
Type Culture Collection (Manassas, VA, USA) and
cultured in DMEM medium supplemented with 10%
heat-inactivated FBS and 1% penicillin/streptomycin.
The cells were maintained in a 5% CO2/95%
air-humidified incubator at 37°C. Danu was dissolved
in DMSO with a stock concentration of 100 mM and
the stock solution was stored at -20°C. Danu was
freshly diluted to the predetermined concentrations
with culture medium. The control cells received the
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vehicle only. Hep3B cells were treated with Danu at
0.01, 0.1, and 0.5 µM for 24 hr, and then subject to flow
cytometric
analysis
and
confocal microscopic
examination. The protein samples were subject to
Western blotting assay.

Quantitative proteomic study using SILAC
Quantitative proteomic experiments were
performed using a SILAC-based approach as
described previously [29, 44]. Briefly, Hep3B cells
were cultured in DMEM-F12 medium (for SILAC)
with (heavy) or without (light) stable isotope labeled
amino acids (13C6 L-lysine and 13C6 15N4 L-arginine)
and 10% dialyzed FBS. Hep3B cells cultured in heavy
medium were treated with 0.5 µM Danu for 24 hr after
six cell doubling times. After treatment with Danu,
Hep3B cells were harvested and lysed with hot lysis
buffer (100 mM Tris base, 4% sodium dodecyl sulfate
[SDS], and 100 mM dithiothreitol), and protein
concentration was determined using ionic detergent
compatibility reagent. Subsequently, equal amounts
of heavy and light protein samples were combined to
reach a total volume of 30–60 µL containing 300–600
µg protein. The combined protein sample was
digested using a filter-aided sample prep (FASP™)
protein digestion kit and desalted using a C18
solid-phase extraction column. The peptide mixtures
(5 µL) were subject to the hybrid linear ion trap (LTQ
Orbitrap XL™, Thermo Fisher Scientific Inc.). Liquid
chromatography-tandem mass spectrometry was
performed using a 10 cm long, 75 µm (inner diameter)
reversed-phase column packed with 5 µm diameter
C18 material having a pore size of 300 Å (New
Objective Inc., Woburn, MA, USA) with a gradient
mobile phase of 2–40% acetonitrile in 0.1% formic acid
at 200 µL per min for 125 min. The Orbitrap full mass
spectrometry scanning was performed at a mass
(m/z) resolving power of 60,000, with positive
polarity in profile mode (M + H+). Peptide SILAC
ratio was calculated using MaxQuant version 1.2.0.13.
The SILAC ratio was determined by averaging all
peptide SILAC ratios from peptides identified of the
same protein. The protein IDs were identified using
Scaffold 4.3.2 from Proteome Software Inc. (Portland,
OR, USA).

Pathway analysis using IPA and DAVID
The pathway was analyzed using ingenuity
pathway analysis (IPA) from QIAGEN (Redwood
City, CA, USA) and the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [45].
DAVID was also used to provide biological functional
interpretation of the potential targets of Danu.
Enrichment scores and Fisher’s exact test P-values
(and corresponding false discovery rate [FDR]) were
http://www.jcancer.org
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calculated to identify which functional related gene
groups were significantly enriched in the target list.
These significant enriched gene groups could explain
the mechanism of action of Danu systematically.

Cell viability assay
The MTT assay was performed to examine
Hep3B cells viability. Hep3B cells were seeded in
96-well culture plates at a density of 8,000 cells per
well. After incubation for 24 hr, the cells were treated
with Danu at different concentrations ranging from
0.01 to 50 μM for 24 hr. In the autophagy inhibition
experiments, the cells were coincubated with Danu
and CQ for 24 hr. Absorbance at the 450 nm
wavelength was measured with a Synergy H4 Hybrid
microplate reader (BioTek Inc., Winooski, VT, USA).
IC50 values were determined using the relative
viability over Danu concentration curve by GraphPad
Prism 6.0 (GraphPad Software Inc., La Jolla, CA,
USA).

Cell cycle distribution analysis
The effect of Danu on cell cycle distribution of
Hep3B cells was examined using flow cytometry as
previously described [46]. Propidium iodide is used
as a DNA stain in cell cycle analysis. A total number
of 1×104 cells were subject to cell cycle analysis using a
flow cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA).

Quantification of cellular apoptosis
The effect of Danu on the apoptosis of Hep3B
cells was quantitated using the annexin V: PE
apoptosis detection kit (BD Biosciences Inc.)
according to the manufacturer’s instruction. In brief,
the cells were collected after Danu treatment at
different concentrations over 24 hr, or evaluated for
different time intervals, and resuspended and
incubated in 100 μL 1 × binding buffer containing 5 µL
annexin V:PE and 5 μL 7-amino-actinomycin D
(7-AAD) in the dark at room temperature for 15 min.
The number of apoptotic cells was analyzed by flow
cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA) within 1 hr.

Quantification of cellular autophagy
To determine the effect of Danu on autophagy in
Hep3B cells, the intracellular autophagy level was
examined using the Cyto-ID® autophagy detection kit
(No.
ENZ-51031-K200)
according
to
the
manufacturer’s instructions. In brief, cells were
collected after Danu treatment at different conditions
and resuspended in 250 µL of assay buffer containing
5% FBS. Following with the addition of 250 µL of the
diluted Cyto-ID® Green stain solution, cells were
incubated at room temperature in the dark for 20 min,
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then cells were collected and washed with 1 × assay
buffer. The percentage of autophagy cells was
analyzed using the green (FL1) channel of a flow
cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA).

Confocal fluorescence microscopic
examination
The cellular autophagy level was further
detected using confocal fluorescence microscopy. The
cells were also dyed with Cyto-ID® green detection
and Hoechst 33342 nuclear stain reagent contained in
the Cyto-ID® autophagy detection kit (No.
ENZ-51031-K200) according to the manufacturer’s
instructions. The cells were examined using a Leica
TCS SP2 laser scanning confocal microscopy (Leica
Microsystems, Wetzlar, Germany) using a standard
FITC filter set for imaging the autophagic signal at
wavelengths of 405/488 nm.

Western blotting analysis
The expression levels of various cellular proteins
were determined using Western blotting assays.
Protein samples were collected in the RIPA buffer (50
mmol HEPES at pH 7.5, 150 mmol NaCl, 10% glycerol,
1.5 mmol MgCl2, 1% Triton-X 100, 1 mmol EDTA at
pH 8.0, 10 mmol sodium pyrophosphate, 10 mmol
sodium fluoride) containing the protease inhibitor
and phosphatase inhibitor cocktails, and centrifuged
at 3,000 × g for 10 min at 4oC. Protein concentrations
were determined using the BCA assay and 20 µg
samples were resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE)
sample loading buffer and electrophoresed on 7−12%
SDS-PAGE mini-gel after thermal denaturation at
95oC for 5 min. Proteins were transferred onto PVDF
membrane at 400 mA for 2 h at 4oC. Membranes were
probed with indicated primary antibody overnight at
4oC and then blotted with respective secondary
anti-mouse or anti-rabbit antibody. Visualization was
performed using Bio-Rad ChemiDocTM XRS system
(Hercules, CA, USA) with enhanced chemiluminescence substrate. The blots were analyzed using
ImageLab 3.0 (Hercules) and protein level was
normalized to the matching densitometric value of
β-actin as internal control.

Statistical analysis
Data are presented as the mean ± standard
deviation (SD). Comparisons of multiple groups were
evaluated by one-way analysis of variance followed
(ANOVA) by Tukey’s multiple comparison
procedure. A value of P<0.05 was considered
statistically different. Assays were performed at least
three times independently.
http://www.jcancer.org
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Results
Proteomic response to Danu treatment in
Hep3B cells
First, we performed a SILAC-based proteomic
study to quantitatively determine the general
proteomic response to 0.5µM Danu treatment in
Hep3B cells. Danu treatment increased the expression
level of 279 protein molecules, but decreased the
expression level of 260 protein molecules (Table S1).
Subsequently, these proteins were subject to IPA and
DAVID analysis. The IPA results showed that 109
signaling pathways were regulated by Danu in Hep3B
cells (Table S2, Figure S1). KEGG pathway analysis
showed that 24 signaling pathways were modulated
by Danu (Table 2). As shown in Table S3, 18
functional clusters were identified to be significantly
enriched (enrichment score > 5). The top five
molecular and cellular functions regulated by Danu in
Hep3B cells (IPA analysis) were cellular growth and
proliferation, protein synthesis, cell death and
survival, RNA post-transcriptional modification, and
gene expression (Table 1). Then we focused on
analyzing the effect of Danu on cell cycle distribution,
apoptosis, and autophagy, which are related to
cellular growth and proliferation, cell death, and
survival.
Table 1. Top five molecular and cellular functions regulated by
Danu in Hep3B cells.
Names
Cellular growth and proliferation
Protein synthesis
Cell death and survival
RNA post-transcriptional modification
Gene expression

P-value range
4.19×10-4 - 7.19×10-33
1.69×10-4 - 3.29×10-30
4.60×10-4 - 8.60×10-30
3.34×10-4 - 8.30×10-22
5.47×10-4 - 4.95×10-20

Molecules
263
138
258
54
153

cycle distribution. We next used flow cytometry to
validate this effect. The data showed that Danu
treatment induced cell cycle arrest at G2/M phase in a
concentration-dependent manner. Compared to the
basal level (15.4%), the percentage of Hep3B cells
arrested at G2/M phase ascended to 57.3% (P<0.001,
Figure 2A) and 53.3% (P<0.001, Figure 2A), when cells
were treated with Danu at 0.1 and 0.5 μM for 24 hr,
respectively. On the contrary, there was a marked
reduction in the number of cells at G1 phase when
treated with 0.1 and 0.5 μM Danu for 24 hr.
Table 2: The KEGG pathways by the DAVID database for the
target list of Danu in Hep3B cells
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Pathway
Spliceosome
Aminoacyl-tRNA biosynthesis
Ribosome
Pathogenic Escherichia coli infection
Glycolysis / Gluconeogenesis
Antigen processing and presentation
Methane metabolism
Fatty acid metabolism
Cysteine and methionine metabolism
Pentose phosphate pathway
Proteasome
Citrate cycle (TCA cycle)
Oocyte meiosis
Prion diseases
Tight junction
Glutathione metabolism
Pyruvate metabolism
Tryptophan metabolism
Systemic lupus erythematosus
Regulation of actin cytoskeleton
Fatty acid elongation in mitochondria
Focal adhesion
Cell cycle
Base excision repair

Gene count
26
12
17
11
11
12
4
8
7
6
8
6
12
6
13
7
6
6
10
17
3
16
11
5

P-Value
5.24×10-10
1.93×10-6
2.28×10-6
2.86×10-4
4.40×10-4
1.68×10-3
1.89×10-3
2.39×10-3
4.67×10-3
5.58×10-3
6.10×10-3
1.41×10-2
1.44×10-2
2.32×10-2
2.42×10-2
2.94×10-2
3.89×10-2
3.89×10-2
4.39×10-2
4.77×10-2
5.18×10-2
5.2×10-2
7.13×10-2
8.16×10-2

Fold Enrichment
4.34
6.15
4.11
4.06
3.85
3.04
14.01
4.20
4.33
5.04
3.58
4.07
2.29
3.60
2.04
2.94
3.15
3.15
2.12
1.66
7.88
1.67
1.85
3.00

Abbreviations: KEGG, Kyoto encyclopedia of genes and genomes; Danu,
danusertib

Danu inhibits the proliferation of Hep3B cells
We first verified the effect of Danu on the
proliferation of Hep3B cells using MTT assay. A
concentration-dependent inhibitory effect of Danu on
the growth of Hep3B cells was observed (Figure 1).

Danu regulates the cell cycle distribution of
Hep3B cells
Compared to the control cells (100%), the
percentage of the viability of Hep3B cells decreased to
91.7, 84.1, 77.9, 70.9, 64.8, 52.4, and 43.1%,
respectively, when cells were treated with Danu at
0.01, 0.1, 0.5, 1, 5, 25, and 50 µM for 24 hr. The IC50
value was 22.03 µM. The results show that Danu
inhibits the proliferation of Hep3B cells.
As shown in Table S2 and Table 2, both IPA
(Pathway No. 30) and DAVID (Pathway No. 23)
analysis have identified the effect of Danu on the cell

Figure 1. Cytotoxicity of Danu towards Hep3B cells determined by the MTT assay.

Danu alters the expression of key cell cycle
regulators in Hep3B cells
We next used Western blotting assay to further
validate the effect of Danu on the cell cycle
http://www.jcancer.org
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Figure 2. Danu treatment arrested Hep3B cells in G2/M phase via regulating the expression of key cell cycle regulators. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5
µM for 24 hr, and then subject to flow cytometric analysis. The protein samples were subject to Western blotting assay. Representative flow cytometric plots of cell cycle
distribution (A) and blots of p-CDC25C (Ser216), p-CDC2/CDK1 (Tyr15), CDC2/CDK1, p-cyclin B1 (Ser133), and cyclin B1 (B). Bar graphs show the percentage of Hep3B cells
in G1, S, and G2/M phases and the relative level of the above proteins. β-Actin was used as the internal control. Data are the mean ± SD of three independent experiments.
*P<0.05, **P<0.001 and ***P<0.001 by one-way ANOVA.

distribution. Our results demonstrated treatment with
Danu at 0.5 μM resulted in a 45.8% (P<0.01, Figure 2B)
decrease in the total level of CDC2 and a 55.3%
(P<0.05, Figure 2B) increase in the phosphorylation (at
Tyr15) level. There was a remarkable decrease (57%,
P<0.01, Figure 2B) in the level of p-cyclin B1 at Ser133,
while there was a marked increase (30.2%, P<0.01,
Figure 2B) in the total level of cyclin B1 when cells
were treated with 0.5 μM Danu. We further detected
the level of p-CDC25C (Ser216), a kinase responsible
for the de-phosphorylation of CDC2 (Tyr15).
Treatment with Danu at 0.5 μM up-regulated the
expression level of p-CDC25C (Ser216) by 77.4%
(P<0.05, Figure 2B). These findings indicate Danu
treatment results in an inactivation of CDC2/CDK1cyclin B1 complex, which leads to cell arrest at G2/M
phase.

Danu induces apoptosis in Hep3B cells
Both IPA (Table S2, Pathway No. 63 and No. 66)
and DAVID (Table S3, Cluster No. 18) analysis have
revealed the effect of Danu on the apoptosis of Hep3B
cells. We next used flow cytometry and Western
blotting assay to validate the pro-apoptotic effect of
Danu. As shown in Figure 3A, compared to the
control cells, treatment with Danu at 0.5 μM resulted
in a 2.16-fold increase in the overall apoptotic rate

(P<0.01, Figure 3A). The Western blotting assays
showed that Danu treatment at 0.5 μM significantly
up-regulated the level of cleaved PARP 1.9-fold, a
marker of cellular apoptosis.
Since DAVID (Table S3, Cluster No. 18) analysis
have demonstrated a number of protein molecules
involved in the regulation of apoptosis, we further
examined the expression levels of pro-apoptosis and
anti-apoptosis proteins. As shown in Figure 3B,
compared to the control cells, there were a 33.5% and
52.1% reduction, respectively, in the level of Bcl-xl
and Bcl-2 (P<0.01, Figure 3B), while there was a
1.9-fold elevation in the level of Bax (P<0.01, Figure
3B), when Hep3B cells were treated with 0.5 μM
Danu. Mitochondrial dysfunction (Table 1, Pathway
No. 42) following remarkable increase in the ratio of
Bax/Bcl-2 leads to the release of cytochrome c.
Indeed, we observed that Danu treatment at 0.1 and
0.5 μM increased the level of cytosolic cytochrome c
by 88.2% and 85.6%, respectively (P<0.01, Figure 3B).
Subsequently, we observed a remarkable increase in
the level of cleaved caspases 9 (1.62-fold) and 3
(1.69-fold). Additionally, Danu also up-regulated the
negative regulator of Bcl-2 family, PUMA, in Hep3B
cells. Treatment of cells with Danu at 0.5 μM resulted
in 2.4-fold increase in the level of PUMA compared to
the control cells (P<0.001, Figure 3B). Taken together,
http://www.jcancer.org
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Figure 3. Danu treatment induced apoptosis via mitochondria-dependent pathway. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and then subject to
flow cytometric analysis. The protein samples were subject to Western blotting assay. Representative flow cytometric plots of cell cycle distribution (A) and blots of cytochrome
c, Bax, Bcl-xl, Bcl-2, cleaved caspase 9, cleaved caspase 3, PUMA, and cleaved PARP (B). Bar graphs show the percentage of autophagic Hep3B cells and the relative level of the
above proteins. β-Actin was used as the internal control. Data are the mean ± SD of three independent experiments. *P<0.05, **P<0.001 and ***P<0.001 by one-way ANOVA.

the results indicate that Danu exhibits via activation
of mitochondria-dependent pathway.

Danu induces autophagy in Hep3B cells
As shown in Table S2 and Table 2, a number of
pathways were regulated by Danu treatment based on
the IPA and DAVID analysis. Of note, near one third
(IPA analysis) or half (DAVID analysis) of them were
involved in the nutrition and energy metabolism.
Functional cluster No. 18 is also in regard to nutrition
and energy metabolic process (Table S3). These
findings indicate the regulatory role of Danu in
intracellular hemostasis.
We speculated that Danu treatment would exert
a significant effect on the autophagy in Hep3B cells. In
order to validate the pro- or anti-autophagic effect of
Danu, flow cytometry, confocal microscopic
examination, and Western blotting assay were
performed.
As shown in Figure 4, treatment with Danu
markedly increased the level of autophagy in a
concentration-dependent
manner.
Our
flow
cytometric data showed treatment with Danu at 0.1
and 0.5 µM for 24 hr resulted in a 3.1- and 3.4-fold
increase in the percentage of autophagic cells
compared to the control cells (basal level = 8.3%)
(P<0.001, Figure 4A). The confocal microscopic
examination showed that autophagic level was

increased 1.9- and 2.7-fold when Hep3B cells were
treated with Danu at 0.1 and 0.5 µM for 24 hr,
respectively (P<0.001, Figure 4B).
As shown in Figure 4C, the result of LC3
turnover assay was positive, since the ratio of
LC3-II/LC3-I was elevated by 41% when cells were
treated with 0.5 µM Danu (P<0.05, Figure 4C). The
expression level of another autophagic marker, beclin
1, was up-regulated (P<0.05, Figure 4C). SQSTM1/
p62 accumulates when autophagy is inhibited, and
decreased level can be observed when autophagy is
induced. Treatment of Hep3B cells with Danu at 0.5
μM resulted in a 32% decrease in the level of
SQSTM1/p62 (P<0.05, Figure 4C). In aggregate, these
results demonstrate the inducing effect of Danu on
autophagy in Hep3B cells.

Danu regulates the PI3K/Akt/mTOR signaling
pathway in Hep3B cells
Accumulating evidence suggest that the
PI3K/Akt/mTOR signaling pathway is involved in
the regulation of both apoptosis and autophagy [47].
Our data have demonstrated that Danu induced
apoptosis and autophagy. As shown in Table 1,
mTOR signaling, one of the top five IPA canonical
pathways, along with PI3K/Akt signaling (Pathway
No. 29), have been regulated by Danu treatment. So
we next used Western blotting assay to validate the
http://www.jcancer.org
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regulatory effect of Danu on this well-known
pathway. Danu treatment at 0.1 and 0.5 µM markedly
inhibited the phosphorylation of PI3K at Tyr199 in
Hep3B cells, but did not impact the expression of total
PI3K, leading to a 22.1% and 39.3% decrease in the
ratio of p-PI3K/PI3K, respectively (P<0.05 or 0.01,
Figure 5). Danu inactivated PI3K resulted in an
inhibition of the phosphorylation of Akt at Ser473.
Consequently, the ratio of p-Akt/Akt decreased
64.6% when cells were exposed to 0.5 µM Danu for 24
hr (P<0.01, Figure 5). Inhibition of mTOR was
detected following the inactivation of PI3K/Akt
pathway in these HCC cells. Danu inhibited the
phosphorylation of mTOR and the ratio of
p-mTOR/mTOR was decreased 39.2% and 43.6%
when treated 0.1 and 0.5 µM Danu, respectively
(P<0.01, Figure 5). Collectively, these findings indicate
that Danu induces apoptosis and autophagy via the
PI3K/Akt/mTOR signaling pathway in Hep3B cells.

Inhibition of autophagy enhances the
anticancer effect of Danu in Hep3B cells
Under
most
circumstances,
autophagy
represents a pro-survival process against apoptosis;
but in other special settings, it culminates in
alternative cell death [47]. So we next used the MTT
assay to examine the role of autophagy in the
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anticancer effect of Danu in Hep3B cells. Coincubation
with 40 μM CQ and 0.5 µM Danu markedly decreased
the viability of Hep3B cells (71.0%), compared to the
group treated with 0.5 µM Danu (91.4%) or 40 μM CQ
(82.5%) alone (P<0.001 or 0.05, Figure 6). These
preliminary data suggest that Danu might trigger a
cyto-protective autophagy in Hep3B cells.

Discussion
Studies have showed that Aurora kinases A and
B are overexpressed in human HCCs which is
associated with aggressive tumor characteristics and
poor prognosis [22, 48, 49]. These findings indicate the
importance of Aurora kinases as potential targets for
the treatment of HCC. A series of Aurora kinase
inhibitors have been tested for HCC treatment in
preclinical and clinical studies [28, 33-35, 50-52]. In the
present study, we evaluated the global proteomic
responses to Danu, including the related molecular
targets and signaling pathways, in Hep3B cells using
a SILAC-based quantitative proteomic approach. The
proteomic study and subsequent validating assays
revealed that Danu inhibited the proliferation and
induced cell cycle arrest, apoptosis, and autophagy in
Hep3B cells, with the involvement of a number of
function proteins and pathways.

Figure 4. Danu treatment induced autophagy. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and then subject to flow cytometric analysis and
confocal fluorescence microscopic examination. The protein samples were subject to Western blotting assay. (A) Histograms show autophagy of HepG2 cells and bar graphs
show the percentage of autophagic Hep3B cells. (B) Representative confocal microscopic images show autophagy of Hep3B cells and bar graph shows the fluorescence level. (C)
Representative blots of LC3-I, LC3-II, beclin 1, and p62 determined by Western blotting assay. β-Actin was used as the internal control. Bar graphs show the relative level of the
above proteins. Data are the mean ± SD of three independent experiments. *P<0.01, **P<0.001, and ***P<0.001 by one-way ANOVA.
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Figure 5. Danu regulates the PI3K/Akt/mTOR signaling pathway. Hep3B cells were treated with Danu at 0.01, 0.1, and 0.5 µM for 24 hr, and the protein samples were subject
to Western blotting assay. Representative blots of phosphorylation level of PI3K, Akt, and mTOR and the total levels of PI3K, Akt, and mTOR, determined by Western blotting
assay. Bar graphs show the ratio of p-PI3K/PI3K, p-Akt/Akt, and p-mTOR/mTOR in Hep3B cells. β-Actin was used as the internal control. Data are the mean ± SD of three
independent experiments. *P<0.05, **P<0.001, and ***P<0.001 by one-way ANOVA.

Figure 6. Inhibition of autophagy enhanced the anticancer effect of Danu. Hep3B
cells were incubated with Danu or CQ alone, or coincubated for 24 hr, and then
subject to the MTT assay. Data are the mean ± SD of three independent experiments.
*P<0.05, **P<0.001, and ***P<0.001 by one-way ANOVA.

SILAC-based proteomics can quantitatively and
globally evaluate the proteomic response to a given
compound and identify its potential targets and
related signaling pathways in vitro and in vivo [38-41].
Our proteomic data demonstrated the molecular
targets regulated by Danu were involved in a number
of important cellular functions, with cellular growth
and proliferation, cell death, and survival being listed
in the top five. Besides, several signaling pathways
relevant to these functions have been revealed, such
as cell cycle regulation, apoptosis signaling, and
Myc-mediated apoptosis signaling. The functional
cluster analysis based on the DAVID also depicted
these regulatory effects of Danu in Hep3B cells. The
proteomic results suggest that Danu may target these
signaling molecules to elicit its anticancer effects in
the treatment of HCC. Notably, we further validated
the proteomic responses to Danu treatment in Hep3B
cells.
Danu inhibits all three members of the Aurora
kinase family, Aurora A, B, and C [28]. Inhibition of

Aurora kinases lead to improper mitotic progression,
including G2/M phase arrest [28]. We examined the
effect of Danu on the cell cycle distribution and found
that Danu treatment induced cell cycle arrest at G2/M
phase in Hep3B cells, which also verified the
proteomic data. In general, a cell with suppressed
CDC2/CDK1-cyclin B1 complex activity would tend
to be arrested in the G2/M phase, whereas a cell with
elevated CDC2/CDK1-cyclin B1 complex activity
would be favored to enter mitosis. We have detected
inhibition of the dephosphorylation of CDC2/CDK1
at Tyr15, inhibition of the phosphorylation of cyclin
B1 at Ser133 and increased expression level of total
CDC2/CDK1, resulting in inactivation of CDC2/
CDK1-cyclin B1 complex and consequently the
inhibition of the cell cycle progression. Our data also
showed that, the upstream regulator of CDC2/CDK1
and CDC25C (Ser216) were involved. In aggregate,
the proteomics and verification data both indicate that
Danu exerts a marked cell cycle arresting effect via
regulation of key functional proteins.
Disruption of mitochondrial function and the
resultant cytochrome c release initiate apoptosis
process, with the latter being activated caspase
cascade, including activation of caspases 9 and 3 [53,
54]. Our proteomic data demonstrated that Danu
regulated mitochondrial function and apoptotic cell
death. In the present study, the flow cytometric and
Western blotting results have verified the
pro-apoptotic effect of Danu. The finding also showed
cytosolic level of cytochrome c was significantly
increased and caspase cascade was markedly
activated in response to Danu treatment, which
contributes to Danu-induced apoptosis of Hep3B
cells. Pro- and anti-apoptotic members of the Bcl-2
family are highly involved in apoptosis [53].
Anti-apoptotic members of Bcl-2 are suppressed by
http://www.jcancer.org
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post-translational modification and/or by increased
expression of PUMA [55]. The proteomic study also
showed a number of proteins were involved in the
regulation of apoptosis. The Western blotting assay
showed that Danu disrupted the balance between Bax
and Bcl-2 with involvement of PUMA.
Autophagy is the major intracellular degradation
system and plays a critical role in maintaining
intracellular hemostasis [56-58]. Under most
circumstances, autophagy emerges as a biological
process that promotes cell survival [56, 57]. In recent
years, the distinct role of autophagy in cell growth,
survival, and death has been demonstrated to be
context-dependent in cancer cells [59]. Under certain
circumstances, the pro-survival functions of
autophagy may be deleterious and lead to cell death
[59]. Our proteomics and verification data both
demonstrated that Danu induced autophagy in
Hep3B cells. The preliminary study showed inhibition
of autophagy with chloroquine markedly decreased
the viability of Hep3B cells. These data suggest that
Danu might trigger a cyto-protective autophagy in
Hep3B cells and supports potential application of
autophagic inhibitors for HCC therapy.
Although apoptosis and autophagy are
regulated by distinct signaling pathways, they have
substantial interconnections in determining cell fate
[60]. In recent years, various signaling pathways have
been
implicated
in
the
up-regulating
or
down-regulating of apoptosis and autophagy,
respectively. The PI3K/Akt/mTOR signaling is a
well-known pathway involved in the regulation of
both apoptosis and autophagy and may contribute to
simultaneous or sequential induction of both
processes [47]. Our proteomic study revealed that
PI3K/Akt/mTOR signaling pathway was regulated
by Danu. Subsequent data demonstrated the Danu
inhibited the phosphorylation of PI3K, Akt, and
mTOR. We deduce that PI3K/Akt/mTOR signaling
pathway might be involved in regulating apoptosis
and autophagy in Hep3B cells, although further
studies are mandatory. Apart from the signaling
pathways, the dual regulatory roles of some key
interconnected molecules in these two pathways have
been identified, such as Bcl-2 family members, beclin
1, caspases, and p53 [47, 61, 62]. In the present study,
the expression of Bcl-2, Bcl-xl, and beclin 1 was
regulated by Danu; but their roles in the crosstalk
between apoptosis and autophagy remain to be
clarified in future studies.
In conclusion, this SILAC proteomic study
shows that Danu regulates a number of functional
proteins and molecular signaling pathways, Danu
inhibits cell proliferation, induces cell cycle arrest,
apoptosis, and cyto-protective autophagy. Inhibition
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of autophagy increases the sensitivity of Hep3B cells
to Danu. More functional and mechanistic studies are
needed to elucidate the role of Danu in the treatment
of HCC.

Supplementary Material
Supplementary figures and tables.
http://www.jcancer.org/v09p2061s1.pdf

Competing Interests
The authors have declared that no competing
interest exists.

References
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018.
Fu J, Wang H. Precision diagnosis and treatment of liver cancer in China.
Cancer Lett. 2018; 412: 283-8.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
incidence and mortality worldwide: sources, methods and major patterns in
GLOBOCAN 2012. Int J Cancer. 2015; 136: E359-86.
Beal EW, Tumin D, Kabir A, Moris D, Zhang XF, Chakedis J, et al. Trends in
the mortality of hepatocellular carcinoma in the United States. J Gastrointest
Surg. 2017.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics
in China, 2015. CA Cancer J Clin. 2016; 66: 115-32.
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al.
Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66:
271-89.
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:
1245-55.
Ringehan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos
Trans R Soc Lond B Biol Sci. 2017; 372.
Are C, Meyer B, Stack A, Ahmad H, Smith L, Qian B, et al. Global trends in the
burden of liver cancer. J Surg Oncol. 2017; 115: 591-602.
Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma:
implications for genomic and immune therapies. Mol Cancer. 2017; 16: 149.
Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of
hepatocellular carcinoma. Semin Diagn Pathol. 2017; 34: 153-9.
Longo V, Gnoni A, Casadei Gardini A, Pisconti S, Licchetta A, Scartozzi M, et
al. Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget.
2017; 8: 33897-910.
Allaire M, Nault JC. Advances in management of hepatocellular carcinoma.
Curr Opin Oncol. 2017; 29: 288-95.
Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond
sorafenib-chemotherapy. J Gastrointest Oncol. 2017; 8: 256-65.
Desai JR, Ochoa S, Prins PA, He AR. Systemic therapy for advanced
hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017; 8: 243-55.
Woo HY, Yoo SY, Heo J. New chemical treatment options in second-line
hepatocellular carcinoma: what to do when sorafenib fails? Expert Opin
Pharmacother. 2017; 18: 35-44.
Ziogas IA, Tsoulfas G. Evolving role of sorafenib in the management of
hepatocellular carcinoma. World J Clin Oncol. 2017; 8: 203-13.
Trojan J, Waidmann O. Role of regorafenib as second-line therapy and
landscape of investigational treatment options in advanced hepatocellular
carcinoma. J Hepatocell Carcinoma. 2016; 3: 31-6.
Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy
and personalized medicine in hepatocellular carcinoma: drug resistance,
mechanisms, and treatment strategies. J Hepatocell Carcinoma. 2017; 4: 93-103.
Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and
tumorigenesis. Mol Cancer Res. 2007; 5: 1-10.
Hilton JF, Shapiro GI. Aurora kinase inhibition as an anticancer strategy. J Clin
Oncol. 2014; 32: 57-9.
Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of
Aurora-A in hepatocellular carcinoma. Clin Cancer Res. 2004; 10: 2065-71.
Borisa AC, Bhatt HG. A comprehensive review on Aurora kinase: Small
molecule inhibitors and clinical trial studies. Eur J Med Chem. 2017; 140: 1-19.
Bayliss R, Burgess SG, McIntyre PJ. Switching Aurora-A kinase on and off at
an allosteric site. FEBS J. 2017; 284: 2947-54.
Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J. Aurora kinases: novel
therapy targets in cancers. Oncotarget. 2017; 8: 23937-54.
Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy.
Nat Rev Cancer. 2017; 17: 93-115.
Zhu Q, Yu X, Zhou ZW, Zhou C, Chen XW, Zhou SF. Inhibition of Aurora A
kinase by alisertib induces autophagy and cell cycle arrest and increases
chemosensitivity in human hepatocellular carcinoma HepG2 cells. Curr
Cancer Drug Targets. 2017; 17: 386-401.

http://www.jcancer.org

Journal of Cancer 2018, Vol. 9
28. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, et al. Preclinical
evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase
inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010; 70:
9846-54.
29. He SJ, Shu LP, Zhou ZW, Yang T, Duan W, Zhang X, et al. Inhibition of Aurora
kinases induces apoptosis and autophagy via AURKB/p70S6K/RPL15 axis in
human leukemia cells. Cancer Lett. 2016; 382: 215-30.
30. Zi D, Zhou ZW, Yang YJ, Huang L, Zhou ZL, He SM, et al. Danusertib induces
apoptosis, cell cycle arrest, and autophagy but inhibits epithelial to
mesenchymal transition involving PI3K/Akt/mTOR signaling pathway in
human ovarian cancer cells. Int J Mol Sci. 2015; 16: 27228-51.
31. Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, et al. Danusertib, a
potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest
and programmed cell death and inhibits epithelial to mesenchymal transition
involving the PI3K/Akt/mTOR-mediated signaling pathway in human
gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015; 9: 1293-318.
32. Li JP, Yang YX, Liu QL, Zhou ZW, Pan ST, He ZX, et al. The pan-inhibitor of
Aurora kinases danusertib induces apoptosis and autophagy and suppresses
epithelial-to-mesenchymal transition in human breast cancer cells. Drug Des
Devel Ther. 2015; 9: 1027-62.
33. Schoffski P, Besse B, Gauler T, de Jonge MJ, Scambia G, Santoro A, et al.
Efficacy and safety of biweekly i.v. administrations of the Aurora kinase
inhibitor danusertib hydrochloride in independent cohorts of patients with
advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and
non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
Ann Oncol. 2015; 26: 598-607.
34. Borthakur G, Dombret H, Schafhausen P, Brummendorf TH, Boissel N,
Jabbour E, et al. A phase I study of danusertib (PHA-739358) in adult patients
with accelerated or blastic phase chronic myeloid leukemia and Philadelphia
chromosome-positive acute lymphoblastic leukemia resistant or intolerant to
imatinib and/or other second generation c-ABL therapy. Haematologica. 2015;
100: 898-904.
35. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, et al.
Randomized phase II study of danusertib in patients with metastatic
castration-resistant prostate cancer after docetaxel failure. BJU Int. 2013; 111:
44-52.
36. Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, et al. A
phase I dose-escalation study of danusertib (PHA-739358) administered as a
24-hour infusion with and without granulocyte colony-stimulating factor in a
14-day cycle in patients with advanced solid tumors. Clin Cancer Res. 2009; 15:
6694-701.
37. Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, et
al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase
inhibitor danusertib in patients with advanced or metastatic solid tumors. J
Clin Oncol. 2009; 27: 5094-101.
38. Tyanova S, Mann M, Cox J. MaxQuant for in-depth analysis of large SILAC
datasets. Methods Mol Biol. 2014; 1188: 351-64.
39. Mann M. Fifteen years of stable isotope labeling by amino acids in cell culture
(SILAC). Methods Mol Biol. 2014; 1188: 1-7.
40. Geiger T, Wisniewski JR, Cox J, Zanivan S, Kruger M, Ishihama Y, et al. Use of
stable isotope labeling by amino acids in cell culture as a spike-in standard in
quantitative proteomics. Nat Protoc. 2011; 6: 147-57.
41. Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for
quantitative proteomics. Methods Mol Biol. 2007; 359: 37-52.
42. Zanivan S, Maione F, Hein MY, Hernandez-Fernaud JR, Ostasiewicz P,
Giraudo E, et al. SILAC-based proteomics of human primary endothelial cell
morphogenesis unveils tumor angiogenic markers. Mol Cell Proteomics. 2013;
12: 3599-611.
43. Geiger T, Madden SF, Gallagher WM, Cox J, Mann M. Proteomic portrait of
human breast cancer progression identifies novel prognostic markers. Cancer
Res. 2012; 72: 2428-39.
44. Qiu JX, Zhou ZW, He ZX, Zhao RJ, Zhang X, Yang L, et al. Plumbagin elicits
differential proteomic responses mainly involving cell cycle, apoptosis,
autophagy, and epithelial-to-mesenchymal transition pathways in human
prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther. 2015; 9: 349-417.
45. Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, et al. The
DAVID Gene Functional Classification Tool: a novel biological module-centric
algorithm to functionally analyze large gene lists. Genome Biol. 2007; 8: R183.
46. Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST, He ZX, et al. Alisertib, an
Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits
epithelial to mesenchymal transition in human epithelial ovarian cancer cells.
Drug Des Devel Ther. 2015; 9: 425-64.
47. Zhao GX, Pan H, Ouyang DY, He XH. The critical molecular interconnections
in regulating apoptosis and autophagy. Ann Med. 2015; 47: 305-15.
48. Lin ZZ, Jeng YM, Hu FC, Pan HW, Tsao HW, Lai PL, et al. Significance of
Aurora B overexpression in hepatocellular carcinoma. Aurora B
Overexpression in HCC. BMC Cancer. 2010; 10: 461.
49. Zhang K, Chen J, Chen D, Huang J, Feng B, Han S, et al. Aurora-A promotes
chemoresistance
in
hepatocelluar
carcinoma
by
targeting
NF-kappaB/microRNA-21/PTEN signaling pathway. Oncotarget. 2014; 5:
12916-35.
50. Aihara A, Tanaka S, Yasen M, Matsumura S, Mitsunori Y, Murakata A, et al.
The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for
hepatocellular carcinoma. J Hepatol. 2010; 52: 63-71.

2071
51. Lin ZZ, Hsu HC, Hsu CH, Yeh PY, Huang CY, Huang YF, et al. The Aurora
kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human
hepatocellular carcinoma. J Hepatol. 2009; 50: 518-27.
52. Benten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, et al.
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular
carcinoma in vitro and in a xenograft mouse model. Neoplasia. 2009; 11:
934-44.
53. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH.
Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying
calcium-dependent apoptosis. Nat Cell Biol. 2003; 5: 1051-61.
54. Fesik SW, Shi Y. Structural biology. Controlling the caspases. Science. 2001;
294: 1477-8.
55. Jeffers JR, Parganas E, Lee Y, Yang C, Wang J, Brennan J, et al. Puma is an
essential mediator of p53-dependent and -independent apoptotic pathways.
Cancer Cell. 2003; 4: 321-8.
56. Yang Z, Klionsky DJ. Eaten alive: a history of macroautophagy. Nat Cell Biol.
2010; 12: 814-22.
57. Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell.
2011; 147: 728-41.
58. Ravanan P, Srikumar IF, Talwar P. Autophagy: The spotlight for cellular stress
responses. Life Sci. 2017.
59. Denton D, Nicolson S, Kumar S. Cell death by autophagy: facts and apparent
artefacts. Cell Death Differ. 2012; 19: 87-95.
60. Song S, Tan J, Miao Y, Li M, Zhang Q. Crosstalk of autophagy and apoptosis:
Involvement of the dual role of autophagy under ER stress. J Cell Physiol.
2017; 232: 2977-84.
61. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy
and apoptosis. Cell Death Differ. 2011; 18: 571-80.
62. Pihan P, Carreras-Sureda A, Hetz C. BCL-2 family: integrating stress
responses at the ER to control cell demise. Cell Death Differ. 2017; 24: 1478-87.

http://www.jcancer.org

